Angiopep 2
TFFYGGSRGKRNNFKTEEY-acid
Description
Application Data
Description
-
Based on the Kinitz domain of human aprotinin. Binds to LRP1 and is able to cross the blood brain barrier.
Application Data
-
Data Sheet Data Sheet Data Sheet Material Safety Data Sheet (MSDS)Catalogue number crb1001191 Molecular Weight 2300.1 Sequence (one letter code) TFFYGGSRGKRNNFKTEEY-acid
Sequence (three letter code) H-Thr-Phe-Phe-Tyr-Gly-Gly-Ser-Arg-Gly-Lys-Arg-Asn-Asn-Phe-Lys-Thr-Glu-Glu-Tyr-OH
Purity >95% Storage -20°C References Demeule et al. (2007). Identification and design of peptides as a new drug delivery system for the brain. J. Pharmacol. Exp. Ther. 324 1064. PMID: 18156463
Demeule et al. (2008). Involvement of the low-density lipoprotein receptor-related protein in the transcytosis of the brain delivery vector Angiopep-2. J Neurochem. 106(4) 1534. PMID: 18489712
Lu et al. (2017). Angiopep-2-conjugated poly(ethylene glycol)-co- poly(ε-caprolactone) polymersomes for dual-targeting drug delivery to glioma in rats. Int J Nanomedicine. 12 2117. PMID: 28356732
Manufactured in: United Kingdom Part of the angiopep family of peptides which have been derived from the Kunitz domain of human aprotinin. These peptides are able to cross the blood brain barrier (BBB) and have been used to facilitate the delivery of pharmacological agents to the brain, for example to target glioblastoma tumours and recurrent brain metastases of pre-treated breast cancers. Angiopep-2 has higher transcytosis capacity and higher brain volume of distribution than aprotinin. Like aprotinin, angiopep-2 interacts with low-density lipoprotein receptor-related protein 1 (LRP1) which is thought to promote its delivery across the BBB via receptor-mediated transcytosis (RMT). However the interaction with LRP1 may not be the only method for angiopep-2 to cross into the brain.